GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: June 27, 2003, 18:02:45 ; Search time 71 Seconds
(without alignments)
666.253 Million cell updates/sec

Title: US-09-922-895-1
Perfect score: 1854
Sequence: 1 MTTSLDTVETFGTTSYYDDV.....LERTSSVSPSTAEPELSIVF 355

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1854	100.0	355	17	AAW03377	CC-chemokine recep
2	1854	100.0	355	18	AAW31850	Human eosinophil e
3	1854	100.0	355	18	AAW27124	Human chemokine re
4	1854	100.0	355	19	AAW51745	Human C-C chemokin
5	1854	100.0	355	22	AAG80109	Human CCR3 protein
6	1854	100.0	355	23	AAE15320	Human chemokine (C
7	1851	99.8	355	17	AAW03376	CC-chemokine recep
8	1851	99.8	355	18	AAW10100	Human C-C chemokin
9	1851	99.8	355	23	ABB07733	Human C-C chemokin
10	1851	99.8	355	23	ABB07240	Human CC chemokine
11	1847	99.6	355	22	ABB56341	Non-endogenous hum
12	1846	99.6	355	19	AAW51744	Human C-C chemokin
13	1826.5	98.5	356	18	AAW25943	Human CCKR3 chemok
14	1781	96.1	355	17	AAW03378	CC-chemokine recep
15	1781	96.1	355	19	AAW51746	Human C-C chemokin
16	1746	94.2	332	23	ABJ03698	Human ovary specif
17	1717	92.6	355	23	ABB79520	Monkey C-C chemoki
18	1181.5	63.7	355	15	AAR52749	C-C chemokine rece
19	1181.5	63.7	355	18	AAW26588	Human MIP-1 alpha/
20	1181.5	63.7	355	18	AAW25751	Human MIP-1alpha/R
21	1181.5	63.7	355	21	AAB20571	Human CC-chemokine
22	1115.5	60.2	355	18	AAW29179	Rat CC chemokine r
23	1045	56.4	295	22	AAG80106	Human CCR1 protein
24	948	51.1	352	22	AAG79089	Amino acid sequenc
25	947	51.1	360	16	AAR79166	Human monocyte che
26	947	51.1	360	18	AAW35833	Human monocyte che
27	947	51.1	360	22	AAG80108	Human CCR2b protei
28	947	51.1	360	22	AAU07614	Human wild-type CC
29	946	51.0	360	22	AAU07613	Human CCR2-64I pol
30	943.5	50.9	352	18	AAW27125	Macaque chemokine
31	941	50.8	360	22	ABB56340	Non-endogenous hum
32	939.5	50.7	371	19	AAW23834	Human CC chemokine
33	938.5	50.6	352	18	AAW27407	Human CCR5. Homo
34	938.5	50.6	352	18	AAW27123	Human chemokine re
35	938.5	50.6	352	19	AAW23835	Human CC chemokine
36	938.5	50.6	352	20	AAW88232	HIV-1 co-receptor
37	938.5	50.6	352	22	AAG80111	Human CCR5 protein
38	938.5	50.6	352	22	AAB82948	Human HIV-1 co-rec
39	938.5	50.6	352	22	AAB83354	Human CCR5 protein
40	938.5	50.6	352	22	AAE04321	Human chemokine re
41	938.5	50.6	352	23	ABB08343	Human chemokine (C
42	938.5	50.6	352	23	AAM52828	Human CC chemokine
43	938.5	50.6	439	20	AAY41280	Fusion protein con
44	937.5	50.6	352	22	AAE07039	Human G-protein ch
45	937.5	50.6	352	22	AAE07048	Human G-protein ch

ALIGNMENTS

RESULT 1
AAW03377
ID AAW03377 standard; Protein; 355 AA.
XX
AC AAW03377;
XX
DT 15-NOV-1996 (first entry)
XX
DE CC-chemokine receptor 3.
XX
KW CC-chemokine receptor 3; CKP-3; Eos-L2; inhibitor; antisense;
KW antiinflammatory; eosinophil.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Region 130..138
FT /note= "amino acids 130-138 comprise a motif
FT conserved among C-X-C and C-C chemokine
FT receptors"
XX
PN WO9622371-A2.
XX
PD 25-JUL-1996.
XX
PF 19-JAN-1996; 96WO-US00608.
XX
PR 19-JAN-1995; 95US-0375199.
XX
PA (BGHM) BRIGHAM & WOMENS HOSPITAL.
PA (CHIL-) CHILDRENS MEDICAL CENT.
PA (LEUK-) LEUKOSITE INC.
XX

PI Gerard CJ, Gerard NP, Mackay CR, Ponath PD, Post TW;
PI Qin S;
XX
DR WPI; 1996-354528/35.
DR N-PSDB; AAT31335.
XX
PT Mammalian chemokine receptor-3 and related nucleic acids - useful to
PT identify receptor inhibitors to treat inflammatory disease, e.g.
PT autoimmune disorders, certain cancers, etc.
XX
PS Claim 10; Page 113-114; 153pp; English.
XX
CC A novel human receptor (AAW03377), designated Eos L2 or C-C chemokine
CC receptor 3 (CKR-3), is involved in leukocyte migration associated
CC with inflammation. Its sequence was deduced from a cDNA clone
CC (AAT31335) isolated from a hyper-eosinophilic syndrome patient. A
CC slightly different amino acid sequence (AAW03376) was deduced from a
CC genomic clone (AAT31334) and a consensus sequence is given in AAW03378.
CC Recombinant CKR-3 can be produced in host cells, and is useful for
CC screening for CKR-3 ligands, promoters and inhibitors. The
CC inhibitors can be used to treat inflammatory disease.
XX
SQ Sequence 355 AA;

Query Match 100.0%; Score 1854; DB 17; Length 355;
Best Local Similarity 100.0%; Pred. No. 5.8e-201;
Matches 355; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60

Qy         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120

Qy        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180

Qy        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240

Qy        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300

Qy        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
              |||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
```

RESULT 2
AAW31850
ID AAW31850 standard; Protein; 355 AA.
XX
AC AAW31850;
XX
DT 07-MAY-1998 (first entry)
XX
DE Human eosinophil eotaxin receptor protein CC CKR3.
XX
KW Eosinophil eotaxin receptor; CC CKR3; human; treatment; dermatitis;
KW atopic condition; allergic rhinitis; conjunctivitis; bronchial asthma;
KW beta-chemokine receptor; viral infection.
XX
OS Homo sapiens.
XX
PN WO9741154-A1.
XX
PD 06-NOV-1997.
XX
PF 24-APR-1997; 97WO-US06568.
XX
PR 17-JAN-1997; 97GB-0000894.
PR 26-APR-1996; 96US-0016158.
PR 26-APR-1996; 96US-0017113.
XX
PA (MERI) MERCK & CO INC.
XX
PI Daugherty BL, Demartino JA, Siciliano SJ, Springer MS;
XX
DR WPI; 1997-549685/50.
DR N-PSDB; AAT93601.
XX
PT New isolated human eosinophil eotaxin receptor - used to develop
PT products for treating and preventing atopic conditions e.g. allergic
PT rhinitis, dermatitis, conjunctivitis and bronchial asthma
XX
PS Claim 5; Page 15; 51pp; English.
XX
CC This is a human eosinophil eotaxin receptor. The 5099 base pair encoding
CC cDNA sequence comprises a 1065 base pair open reading frame encoding this
CC 355 amino acid eosinophil eotaxin receptor protein, flanked by a 5'
CC genomic DNA sequence and a 3' terminator region. This novel eosinophil
CC eotaxin receptor is a human beta-chemokine receptor designated CC CKR3.
CC Agents which bind to this eosinophil eotaxin receptor can be used for
CC the treatment and prevention of atopic conditions such as allergic
CC rhinitis, dermatitis, conjunctivitis and bronchial asthma. Agents which
CC block this eosinophil eotaxin receptor can be used to prevent viral
CC infection in healthy individuals and slow or halt viral progression
CC in infected patients.
XX
SQ Sequence 355 AA;

Query Match 100.0%; Score 1854; DB 18; Length 355;
Best Local Similarity 100.0%; Pred. No. 5.8e-201;
Matches 355; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60

Qy         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120

Qy        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180

Qy        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240

Qy        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300

Qy        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
              |||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
```

RESULT 3
AAW27124
ID AAW27124 standard; Protein; 355 AA.
XX
AC AAW27124;
XX
DT 14-DEC-1997 (first entry)
XX
DE Human chemokine receptor 88-2B.
XX
KW Chemokine receptor 88-2B; atherosclerosis; rheumatoid arthritis;

```
KW   tumour; asthma; viral infection; AIDS; inflammation;
KW   autoimmune disease; therapy; diagnosis; leukocyte trafficking;
KW   G protein coupled receptor; ligand; modulator; antibody; human.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Domain          1..36
FT                   /label= Extracellular_domain
FT   Domain          60..71
FT                   /label= Intracellular_domain
FT   Domain          93..107
FT                   /label= Extracellular_domain
FT   Domain          131..151
FT                   /label= Intracellular_domain
FT   Domain          171..196
FT                   /label= Extracellular_domain
FT   Domain          219..240
FT                   /label= Intracellular_domain
FT   Domain          263..284
FT                   /label= Extracellular_domain
FT   Domain          306..355
FT                   /label= Intracellular_domain
XX
PN   WO9722698-A2.
XX
PD   26-JUN-1997.
XX
PF   20-DEC-1996;   96WO-US20759.
XX
PR   07-JUN-1996;   96US-0661393.
PR   20-DEC-1995;   95US-0575967.
XX
PA   (ICOS-) ICOS CORP.
XX
PI   Gray PW,  Raport CJ,  Schweickart VL;
XX
DR   WPI; 1997-341689/31.
DR   N-PSDB; AAT85162.
XX
PT   New nucleic acid encoding chemokine receptors 88-2B and 88C - used
PT   to modulate leukocyte trafficking, e.g. for treatment of
PT   inflammation, tumours, viral infections, autoimmune diseases, etc.
XX
PS   Claim 1; Page 50-51; 65pp; English.
XX
CC   This polypeptide sequence comprises novel human chemokine receptor
CC   88-2B, a G protein coupled receptor that is involved in leukocyte
CC   trafficking.  Its amino sequence was deduced from a cDNA clone
CC   (AAT85162) isolated from a macrophage library.  It shows 72% identity
CC   to CCCKR1.  Chemokine receptor 88C (see AAW27123) has also been
CC   identified.  88C and 88-2B receptors and their polypeptide fragments
CC   can be produced in transformed host cells.  The receptors, peptides
CC   comprising one or more of the extracellular or intracellular
CC   domains, and anti-receptor antibodies can be used to modulate
CC   receptor activities, particularly ligand and G protein binding, and
CC   are potentially potentially useful in the treatment of
CC   atheroslerosis, rheumatoid arthritis, tumours, asthma, viral
CC   infection, AIDS, inflammatory conditions, pathological immune
CC   response, abnormal haematopoietic processes etc.
XX
SQ   Sequence   355 AA;

  Query Match            100.0%;  Score 1854;  DB 18;  Length 355;
  Best Local Similarity  100.0%;  Pred. No. 5.8e-201;
  Matches  355;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60

Qy         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120

Qy        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180

Qy        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240

Qy        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300

Qy        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
              |||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355


RESULT 4
AAW51745
ID   AAW51745 standard; Protein; 355 AA.
XX
AC   AAW51745;
XX
DT   28-SEP-1998  (first entry)
XX
DE   Human C-C chemokine receptor 3.
XX
KW   C-C chemokine receptor 3; CKR-3; CCR3; Eos L2; human;
KW   G protein-coupled receptor; leukocyte; antibody; antagonist;
KW   inflammation; allergy; asthma; graft rejection; infection;
KW   autoimmune disease; drug screening; therapy.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 24
FT                   /note= "conserved cysteine residue"
FT   Misc-difference 106
FT                   /note= "conserved cysteine residue"
FT   Misc-difference 183
FT                   /note= "conserved cysteine residue"
FT   Misc-difference 273
FT                   /note= "conserved cysteine residue"
FT   Peptide         130..138
FT                   /note= "C-C chemokine receptor conserved motif"
FT   Modified-site   231
FT                   /note= "protein kinase C phosphorylation site"
FT   Modified-site   333
FT                   /note= "protein kinase C phosphorylation site"
XX
PN   WO9814480-A1.
XX
PD   09-APR-1998.
XX
PF   24-SEP-1997;   97WO-US17103.
XX
PR   30-SEP-1996;   96US-0720565.
XX
PA   (LEUK-) LEUKOSITE INC.
XX
PI   Mackay CR,  Ponath PD;
XX
DR   WPI; 1998-286418/25.
DR   N-PSDB; AAV07403.
XX
PT   Antibodies to chemokine receptor-3 protein - useful for diagnosis
PT   and treatment of inflammatory conditions, e.g. allergy, asthma,
PT   autoimmune disease, graft rejection or cancer
XX
PS   Example 2; Page 136-137; 185pp; English.
XX
```

CC This polypeptide comprises novel human C-C chemokine receptor 3,
CC also designated CKR-3, CCR3 or Eos L2, that binds and mediates
CC chemotaxis in response to chemokines such as eotaxin, RANTES and
CC MCP-3. Its amino acid sequence was deduced from an isolated
CC cDNA sequence (see AAV07403). It differs slightly from the
CC sequence (see AAW51744) deduced from genomic DNA (see AAV07402); a
CC consensus sequence for CKR-3 is provided (see AAW51746). The
CC invention relates to isolated and/or recombinant nucleic acids
CC encoding CKR-3, isolated or recombinant CKR-3 polypeptides,
CC recombinant nucleic acid constructs, host cells useful for
CC production of recombinant CKR-3 proteins, to antibodies reactive
CC with the receptors, and to methods of using these products to
CC identify ligands, antagonists and agonists of receptor function.
CC Inhibitors of CKR-3 can be used to treat: inflammatory or allergic
CC diseases and conditions, including respiratory allergic diseases
CC such as asthma, allergic rhinitis, hypersensitivity lung disease,
CC hypersensitivity pneumonitis, eosinophilic pneumonia (e.g.
CC Loeffler's syndrome, chronic eosinophilic pneumonia, interstitial
CC lung disease (ILD) e.g. idiopathic pulmonary fibrosis or ILD
CC associated with rheumatoid arthritis, systemic lupus erythematosus,
CC ankylosing spondylitis, systemic sclerosis, Sjogren's syndrome,
CC polymyositis or dermatomyositis), systemic anaphylaxis or
CC hypersensitivity responses, drug allergy, insect sting allergy,
CC inflammatory bowel disease, such as Crohn's disease and ulcerative
CC colitis, spondyloarthropathy, scleroderma, psoriasis, inflammatory
CC dermatosis such as dermatitis, eczema, atopic dermatitis,
CC allergic contact dermatitis, urticaria, vasculitis (e.g. necrotizing,
CC cutaneous and hypersensitivity vasculitis); eosinphilic myositis
CC and eosinophilic fasciitis; autoimmune diseases such as rheumatoid
CC arthritis, psoriatic arthritis, multiple sclerosis, systemic lupus
CC erythematosus, myasthenia gravis, juvenile onset diabetes,
CC glomerulonephritis, autoimmune thyroiditis and Behcet's disease;
CC graft rejection, including allograft rejection or graft-versus-host
CC disease; cancers with leukocyte infiltration of the skin or organs;
CC and also reperfusion injury, atherosclerosis, certain haematologic
CC malignancies, septic shock and endotoxic shock. Promoters of CKR-3
CC function can be used for treating: immunosuppression e.g. in AIDS
CC patients or individuals undergoing radiation therapy, chemotherapy,
CC therapy for autoimmune disease or other drug therapy, and
CC immunosuppression due congenital deficiency in receptor function or
CC other causes; and infectious diseases such as parasitic diseases,
CC including helminth infections, such as nematodes (round worms).
CC The agents can also be used for detection and diagnosis.
XX
SQ Sequence 355 AA;

Query Match 100.0%; Score 1854; DB 19; Length 355;
Best Local Similarity 100.0%; Pred. No. 5.8e-201;
Matches 355; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60

Qy         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120

Qy        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180

Qy        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240

Qy        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300

Qy        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
              |||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
```

RESULT 5
AAG80109
ID AAG80109 standard; Protein; 355 AA.
XX
AC AAG80109;
XX
DT 17-JAN-2002 (first entry)
XX
DE Human CCR3 protein.
XX
KW Chemokine; tumour diagnosis; colorectal; prostatic; organ rejection;
KW inflammation; autoimmune disease; metastasis; bronchial asthma; lupus;
KW chronic bowel inflammation; rheumatoid arthritis; cytostatic;
KW antiinflammatory; antiasthmatic; immunosuppressive; dermatological;
KW antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO200172830-A2.
XX
PD 04-OCT-2001.
XX
PF 02-APR-2001; 2001WO-EP03708.
XX
PR 31-MAR-2000; 2000DE-1016013.
XX
PA (IPFP-) IPF PHARM GMBH.
PA (FORS/) FORSSMANN U.
XX
PI Forssmann W, Adermann K, Heitland A, Spodsberg N;
XX
DR WPI; 2001-626256/72.
XX
PT Diagnostic agent containing two or more receptor-specific ligands,
PT useful for detecting tumors, inflammation etc., also therapeutic use of
PT ligand inhibitors -
XX
PS Disclosure; Page 9; 26pp; German.
XX
CC This invention describes a novel diagnostic agent (A) comprising at least
CC two different ligands (I) for receptors (II) that are implicated in
CC disease. (A) are used for the diagnosis of tumors (especially colorectal
CC or prostatic), organ rejection, inflammation and autoimmune diseases.
CC Also inhibitors of (I) are used therapeutically against tumors (and their
CC metastases), inflammation (particularly bronchial asthma or chronic bowel
CC inflammation), or autoimmune diseases (rheumatoid arthritis or lupus),
CC where the (cardio)vascular, lymphatic, respiratory, nervous, digestive,
CC endocrine, motor or urogenital systems or skin are affected, and bone
CC marrow diseases. The products of the invention are chemokine derivatives
CC which have cytostatic, antiinflammatory, antiasthmatic,
CC immunosuppressive, dermatological, antirheumatic, antiarthritic.
CC Chemokines act on specific tumor and inflammatory cells through a
CC constellation of chemokine receptors (CR), which control migration and
CC proliferation of these cells. AAG80045-AAG80128 represent human chemokine
CC fragments used to illustrate the method of the invention.
XX
SQ Sequence 355 AA;

Query Match 100.0%; Score 1854; DB 22; Length 355;
Best Local Similarity 100.0%; Pred. No. 5.8e-201;
Matches 355; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60

Qy         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120

Qy        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180
```

```
                  ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180

Qy        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240
                  ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240

Qy        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300
                  ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300

Qy        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
                  |||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355


RESULT 6
AAE15320
ID   AAE15320 standard; Protein; 355 AA.
XX
AC   AAE15320;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human chemokine (C-C motif) receptor 3 (CCR3) protein.
XX
KW   Human; chemokine (C-C motif) receptor 3; CCR3 gene; haplotyping;
KW   genotyping; type IV hypersensitivity reaction; HIV-1; gene therapy;
KW   human immunodeficiency virus 1; single nucleotide polymorphism; SNP;
KW   chromosome 3p21.3.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 351
FT                   /note= "Leu at this position is replaced with Pro
FT                   due to single nucleotide polymorphism (SNP)"
XX
PN   WO200187908-A2.
XX
PD   22-NOV-2001.
XX
PF   18-MAY-2001; 2001WO-US16278.
XX
PR   18-MAY-2000; 2000US-205191P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Choi JY,  Kazemi A,  Koshy B;
XX
DR   WPI; 2002-055681/07.
DR   N-PSDB; AAD25221, AAD25222.
XX
PT   Isolated polymorphic variants of chemokine (C-C motif) receptor 3
PT   (CCR3) gene useful for studying function of CCR3, expressing the CCR3
PT   protein and to screen drugs to treat CCR3 activity-related diseases -
XX
PS   Claim 28; Fig 3; 53pp; English.
XX
CC   The invention relates to genetic variants of human chemokine (C-C motif)
CC   receptor 3 (CCR3) gene. The invention also relates to compositions and
CC   methods for haplotyping and/or genotyping the CCR3 gene in an individual.
CC   Polynucleotides of the invention are useful for studying the expression
CC   and function of CCR3 and in expressing CCR3 proteins for use in screening
CC   candidate drugs to treat diseases related to CCR3 activity. They are also
CC   used in gene therapy. The polymorphism and haplotype data is useful for
CC   validating whether CCR3 is a suitable target for drugs to treat type IV
CC   hypersensitivity reactions and human immunodeficiency virus (HIV)-1,
CC   screening for such drugs and reducing bias cells in clinical trials of
CC   such drugs. The genotyping method is useful for determining whether an
CC   individual has one haplotype or haplotype pairs. The haplotyping method
CC   is useful for improving the efficiency and outcome of several steps in
CC   the discovery and development of drugs for treating diseases associated
CC   with CCR3 activity such as type IV hypersensitivity reactions and HIV-1.
CC   The present sequence is human CCR3 protein. The CCR3 gene is located on
CC   chromosome 3p21.3.
XX
SQ   Sequence   355 AA;

  Query Match             100.0%;  Score 1854;  DB 23;  Length 355;
  Best Local Similarity   100.0%;  Pred. No. 5.8e-201;
  Matches  355;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60

Qy         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120

Qy        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180

Qy        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240

Qy        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300

Qy        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
              |||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355


RESULT 7
AAW03376
ID   AAW03376 standard; Protein; 355 AA.
XX
AC   AAW03376;
XX
DT   15-NOV-1996  (first entry)
XX
DE   CC-chemokine receptor 3.
XX
KW   CC-chemokine receptor 3; CKP-3; Eos-L2; inhibitor; antisense;
KW   antiinflammatory; eosinophil.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Region          130..138
FT                   /note= "amino acids 130-138 comprise a motif
FT                          conserved among C-X-C and C-C chemokine
FT                          receptors"
XX
PN   WO9622371-A2.
XX
PD   25-JUL-1996.
XX
PF   19-JAN-1996;   96WO-US00608.
XX
PR   19-JAN-1995;   95US-0375199.
XX
PA   (BGHM ) BRIGHAM & WOMENS HOSPITAL.
PA   (CHIL-) CHILDRENS MEDICAL CENT.
PA   (LEUK-) LEUKOSITE INC.
XX
PI   Gerard CJ,  Gerard NP,  Mackay CR,  Ponath PD,  Post TW;
PI   Qin S;
XX
DR   WPI; 1996-354528/35.
DR   N-PSDB; AAT31334.
```

```
XX
PT   Mammalian chemokine receptor-3 and related nucleic acids - useful to
PT   identify receptor inhibitors to treat inflammatory disease, e.g.
PT   autoimmune disorders, certain cancers, etc.
XX
PS   Claim 10; Page 110-111; 153pp; English.
XX
CC   A novel human receptor (AAW03376), designated Eos L2 or C-C chemokine
CC   receptor 3 (CKR-3), is involved in leukocyte migration associated
CC   with inflammation.  Its sequence was deduced from a genomic DNA
CC   clone (AAT31334).  A slightly different amino acid sequence (AAW03377)
CC   was deduced from a cDNA clone (AAT31335) and a consensus sequence
CC   is given in AAW03378.  Recombinant CKR-3 can be produced in host
CC   cells, and is useful for screening for CKR-3 ligands, promoters
CC   and inhibitors.  The inhibitors can be used to treat inflammatory
CC   disease.
XX
SQ   Sequence   355 AA;

  Query Match             99.8%;  Score 1851;  DB 17;  Length 355;
  Best Local Similarity   99.7%;  Pred. No. 1.3e-200;
  Matches  354;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60

Qy         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120

Qy        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180

Qy        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240

Qy        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300
              ||||||||||||||||||||||||||||||||:|||||||||||||||||||||||||||
Db        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERTKHLDLVMLVTEVIAYSHCCMNPVI 300

Qy        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
              |||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355


RESULT 8
AAW10100
ID   AAW10100 standard; Protein; 355 AA.
XX
AC   AAW10100;
XX
DT   30-SEP-1997  (first entry)
XX
DE   Human C-C chemokine receptor 3.
XX
KW   Human; eotaxin; eosinophil; chemoattractant; stimulation;
KW   accumulation; attraction; chemotaxis; diagnosis; prevention;
KW   treatment; disease; inflammation; allergy; asthma; rhinitis;
KW   hypersensitivity; lung; pneumonia; Loeffler's; syndrome;
KW   interstitial; ILD; idiopathic pulmonary fibrosis;
KW   rheumatoid arthritis; systemic; lupus erythematosus; SLE;
KW   ankylosing spondylitis; sclerosis; Sjorgen's; polymyositis;
KW   dermatomyositis; bowel; anaphylaxis; drug; penicillin;
KW   cephalosporin; insect sting; Crohn's; ulcerative colitis;
KW   spondyloarthropathy; scleroderma; psoriasis; dermatosis;
KW   dermatitis; eczema; atopic; urticaria; necrotising; cutaneous;
KW   vasculitis; myositis; fascitis; multiple sclerosis;
KW   myasthenia gravis; juvenile onset diabetes; glomerulonephritis;
KW   autoimmune; thyroiditis; Bechet's; graft; rejection;
KW   transplantation; allograft; graft versus host; cancer;
KW   leukocyte infiltration; reperfusion injury; atherosclerosis;
KW   haematologic malignancy; septic; endotoxic; shock;
KW   polymyositis; dermatomyositis; immunosuppression; immunodeficiency;
KW   AIDS; radiation therapy; chemotherapy; autoimmune; corticosteroid;
KW   C-C chemokine receptor 3; CRK3.
XX
OS   Homo sapiens.
XX
PN   WO9700960-A1.
XX
PD   09-JAN-1997.
XX
PF   21-JUN-1996;   96WO-US10723.
XX
PR   23-JUN-1995;   95US-0494093.
XX
PA   (LEUK-) LEUKOSITE INC.
XX
PI   MacKay C,  Newman W,  Ponath PD,  Qin S,  Ringler DJ;
XX
DR   WPI; 1997-087387/08.
DR   N-PSDB; AAT58783.
XX
PT   New isolated human eotaxin gene - used to develop prods. for the
PT   diagnosis and treatment of e.g. inflammation, allergies, auto-immune
PT   disease, infections and tumours
XX
PS   Example 7; Pages 98-99; 130pp; English.
XX
CC   The present sequence is human C-C chemokine receptor 3 (CRK3),
CC   to which human eotaxin (hE), an eosinophil specific chemoattractant
CC   capable of stimulating eosinophil accumulation and/or attracting
CC   eosinophils (including chemotaxis), binds.
CC   hE can be used to develop products for the diagnosis, prevention or
CC   treatment of hE associated diseases or conditions. The products can
CC   be used to treat inflammatory or allergic diseases and conditions,
CC   including respiratory allergic diseases (e.g. asthma, allergic
CC   rhinitis, hypersensitivity lung diseases or pneumonitis,
CC   eosinophilic pneumonias such as Loeffler's syndrome and chronic
CC   eosinophilic pneumonia, interstitial lung diseases (ILD) such as
CC   idiopathic pulmonary fibrosis or ILD associated with rheumatoid
CC   arthritis, systemic lupus erythematosus (SLE), ankylosing
CC   spondylitis, systemic sclerosis, Sjorgen's syndrome, polymyositis
CC   or dermatomyositis), systemic anaphylaxis or hypersensitivity
CC   responses, drug allergies (e.g. to penicillin and cephalosporins),
CC   insect sting allergies, inflammatory bowel diseases (e.g. Crohn's
CC   disease and ulcerative colitis), spondyloarthropathies,
CC   scleroderma, psoriasis and inflammatory dermatoses (e.g.
CC   dermatitis, eczema, atopic dermatitis, allergic contact dermatitis,
CC   urticaria and necrotising, cutaneous and hypersensitivity
CC   vasculitis), eosinophilic myositis and fascitis, multiple
CC   sclerosis, SLE, myasthenia gravis, juvenile onset diabetes,
CC   glomerulonephritis, autoimmune thyroiditis, Bechet's disease, graft
CC   rejection (e.g in transplantation) including allograft rejection or
CC   graft versus host disease and cancers with leukocyte infiltration
CC   of the skin or organs. The products can also be used to treat other
CC   diseases or conditions requiring the inhibition of undesirable
CC   inflammatory responses, including reperfusion injury,
CC   atherosclerosis, certain haematologic malignancies, cytokine
CC   induced toxicity (e.g. septic or endotoxic shock), polymyositis,
CC   dermatomyositis, immunosuppression (e.g. in individuals with
CC   immunodeficiency syndromes such as AIDS, undergoing radiation
CC   therapy, chemotherapy, therapy for autoimmune disease or other drug
CC   therapy, such as corticosteroid therapy, which causes
CC   immunosuppression), immunosuppression due to (e.g. congenital)
CC   deficiency (e.g in eotaxin) or infectious diseases such as parasitic
CC   diseases.
CC   Degenerate primers based on the guinea pig eotaxin amino acid
CC   sequence were used for the reverse transcriptase polymerase chain
CC   reaction (RT-PCR) amplification of RNA isolated from inflamed,
CC   eosinophilic lung tissue obtained from Balb/c mice sensitised to
CC   ovalbumin. The amplification product was used as a probe to screen
CC   a human genomic library in vector EMBL3 SP6/T7 to obtain the hE
```

```
CC   gene.
XX
SQ   Sequence   355 AA;

  Query Match             99.8%;  Score 1851;  DB 18;  Length 355;
  Best Local Similarity   99.7%;  Pred. No. 1.3e-200;
  Matches  354;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60

Qy         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120

Qy        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180

Qy        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240

Qy        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300
              ||||||||||||||||||||||||||||||||||:||||||||||||||||||||||||||
Db        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERTKHLDLVMLVTEVIAYSHCCMNPVI 300

Qy        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355


RESULT 9
ABB07733
ID   ABB07733 standard; Protein; 355 AA.
XX
AC   ABB07733;
XX
DT   10-JUN-2002  (first entry)
XX
DE   Human C-C chemokine receptor 3 (CCR3) protein.
XX
KW   Mucosae-associated epithelial chemokine; MEC; C-C chemokine receptor;
KW   CCR3; CCR10; anti-inflammatory; cytostatic; immunomodulator; anti-viral;
KW   antibacterial; chemokine; human.
XX
OS   Homo sapiens.
XX
PN   WO200214532-A2.
XX
PD   21-FEB-2002.
XX
PF   15-AUG-2001; 2001WO-US25734.
XX
PR   15-AUG-2000; 2000US-0638914.
XX
PA   (MILL-) MILLENNIUM PHARM INC.
PA   (STRD ) UNIV LELAND STANFORD JUNIOR.
XX
PI   Butcher EC,  Kunkel EJ,  Pan J,  Soler-Ferran D;
XX
DR   WPI; 2002-269204/31.
DR   N-PSDB; ABL40462.
XX
PT   Identifying modulators of mucosae-associated epithelial chemokine (MEC)
PT   receptors 3 or 10 (CCR3/10), useful for treating inflammatory diseases,
PT   comprises detecting formation of MEC-CCR3/10 complex or modulation of a
PT   MEC-induced response -
XX
PS   Example 2; Fig 5; 92pp; English.
XX
CC   The invention relates to identifying agents that inhibit or promote the
CC   binding of a mammalian mucosae-associated epithelial chemokine (MEC) to
CC   a mammalian C-C chemokine receptor 3 (CCR3) or 10 (CCR10). The method
CC   involves: (a) detecting or measuring the formation of a complex between
CC   the MEC, and the CCR3 or CCR10; or (b) determining the ability of the
CC   test agent to inhibit or augment a MEC-induced response. An augmentation
CC   of complex formation, relative to a control, is indicative that the agent
CC   is a promoter. The method is useful for identifying modulators (e.g.
CC   inhibitors or promoter) of MEC-induced functions of CCR3 and/or CCR10.
CC   The inhibitors are useful for treating inflammatory diseases or
CC   conditions in a subject, e.g. oral inflammatory condition (e.g. Sjogren's
CC   syndrome or Behcet's syndrome), mastitis, chronic obstructive lung
CC   disease, asthma, inflammatory bowel disease (e.g. Crohn's disease,
CC   ulcerative colitis or celiac disease), IgA nephropathy or dermatitis
CC   herpetiformis. The promoters are useful for treating cancers (e.g. solid
CC   tumours or cutaneous T cell lymphoma), neoplastic disease, retinopathy,
CC   macular degeneration, bacterial infections, tuberculoid leprosy, viral
CC   infections, AIDS, neutropenias or bronchiectasis. The present sequence
CC   represents the human CCR3 protein.
XX
SQ   Sequence   355 AA;

  Query Match             99.8%;  Score 1851;  DB 23;  Length 355;
  Best Local Similarity   99.7%;  Pred. No. 1.3e-200;
  Matches  354;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60

Qy         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120

Qy        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180

Qy        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240

Qy        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300
              ||||||||||||||||||||||||||||||||||:||||||||||||||||||||||||||
Db        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERTKHLDLVMLVTEVIAYSHCCMNPVI 300

Qy        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355


RESULT 10
ABB07240
ID   ABB07240 standard; Protein; 355 AA.
XX
AC   ABB07240;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Human CC chemokine receptor 3 (CCR3).
XX
KW   CC chemokine receptor-3; CCR3; antiallergic; antiinflammatory; human;
KW   antiasthmatic; ophthalmological; dermatological; immunosuppressive;
KW   antipruritic.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         327..330
FT                   /note= "internalisation site; the modified CCR3 receptor
FT                         comprises a deletion or mutation of the
FT                         internalisation site"
FT   Region          333..353
FT                   /note= "the modified CCR3 receptor comprises a deletion
```

FT or mutation of at least one phosphorylation site
FT selected from positions 333, 339, 340, 341, 343,
FT 346 and 353"
XX
PN WO200192520-A1.
XX
PD 06-DEC-2001.
XX
PF 31-MAY-2001; 2001WO-EP06195.
XX
PR 01-JUN-2000; 2000GB-0013345.
XX
PA (GLAX) GLAXO GROUP LTD.
XX
PI Barnes AA, Fraser NJ, O'Shaughnessy CT, Wise A;
XX
DR WPI; 2002-114347/15.
DR N-PSDB; ABA94340.
XX
PT Modified CC chemokine receptor-3 useful for identifying modulators of
PT eotaxin-mediated CCR3 receptor for treating allergic and inflammatory
PT disorders, comprises modifications to stabilize or enhance surface
PT expression -
XX
PS Claim 1; Page 24-25; 29pp; English.
XX
CC The invention relates to a CC chemokine receptor-3 (CCR3) modified to
CC stabilize or enhance expression of the receptor in a cell membrane.
CC Assays for investigating properties of the CCR3 receptor are useful for
CC the identification of modulators of eotaxin-mediated CCR3 receptor
CC activity. The identified modulators are useful in the treatment of
CC prophylaxis of allergic or inflammatory disorders which are responsive to
CC regulation of CCR3 receptor activity. The agents are also useful in the
CC treatment of allergy or asthma as well as ophthalmological, inflammatory,
CC gastrointestinal, dermatological, respiratory or pruritic disorders. The
CC agents are useful for treating conjectivitis, inflammatory bowel disease,
CC eczema, allergic rhinitis, nasal polyposis, atopic dermatitis and
CC pruritis, chronic obstructive pulmonary disease (COPD) and other lung
CC disorders and immune disease. The present sequence represents the human
CC CCR3 receptor.
XX
SQ Sequence 355 AA;

Query Match 99.8%; Score 1851; DB 23; Length 355;
Best Local Similarity 99.7%; Pred. No. 1.3e-200;
Matches 354; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60

Qy         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120

Qy        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180

Qy        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240

Qy        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300
              ||||||||||||||||||||||||||||||||||:||||||||||||||||||||||||||
Db        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERTKHLDLVMLVTEVIAYSHCCMNPVI 300

Qy        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
```

RESULT 11

ABB56341
ID ABB56341 standard; Protein; 355 AA.
XX
AC ABB56341;
XX
DT 18-FEB-2002 (first entry)
XX
DE Non-endogenous human GPCR protein, SEQ ID NO: 475.
XX
KW Human; G protein-coupled receptor; GPCR; non-endogenous; mutant;
KW constitutively activated GPCR; agonist; disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200177172-A2.
XX
PD 18-OCT-2001.
XX
PF 05-APR-2001; 2001WO-US11098.
XX
PR 07-APR-2000; 2000US-195747P.
XX
PA (AREN-) ARENA PHARM INC.
XX
PI Lehmann-Bruinsma K, Liaw CW, Lin I;
XX
DR WPI; 2001-648759/74.
DR N-PSDB; ABI97977.
XX
PT Identifying agonists of G protein-coupled receptors (GPCRs) for use in
PT disease treatment, comprises contacting candidate compounds with
PT versions of GPCRs -
XX
PS Claim 1; Page 276-277; 394pp; English.
XX
CC The invention relates to G protein-coupled receptors (GPCRs) for which
CC the endogenous ligand has been identified. Non-endogenous
CC constitutively activated versions of known GPCRs are used in the
CC invention for the direct identification of candidate compounds as
CC receptor agonists, inverse agonists or partial agonists. Such
CC agonists are useful as therapeutic agents for diseases or disorders
CC associated with GPCRs. The present sequence is a non-endogenous
CC version of a known human GPCR.
XX
SQ Sequence 355 AA;

Query Match 99.6%; Score 1847; DB 22; Length 355;
Best Local Similarity 99.7%; Pred. No. 3.6e-200;
Matches 354; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60

Qy         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120

Qy        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180

Qy        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAKRL 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||
Db        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAKRL 240

Qy        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300

Qy        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355

RESULT 12
AAW51744
ID   AAW51744 standard; Protein; 355 AA.
XX
AC   AAW51744;
XX
DT   28-SEP-1998  (first entry)
XX
DE   Human C-C chemokine receptor 3.
XX
KW   C-C chemokine receptor 3; CKR-3; CCR3; Eos L2; human;
KW   G protein-coupled receptor; leukocyte; antibody; antagonist;
KW   inflammation; allergy; asthma; graft rejection; infection;
KW   autoimmune disease; drug screening; therapy.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 24
FT                   /note= "conserved cysteine residue"
FT   Misc-difference 106
FT                   /note= "conserved cysteine residue"
FT   Misc-difference 183
FT                   /note= "conserved cysteine residue"
FT   Misc-difference 273
FT                   /note= "conserved cysteine residue"
FT   Peptide         130..138
FT                   /note= "C-C chemokine receptor conserved motif"
FT   Modified-site   231
FT                   /note= "protein kinase C phosphorylation site"
FT   Modified-site   333
FT                   /note= "protein kinase C phosphorylation site"
XX
PN   WO9814480-A1.
XX
PD   09-APR-1998.
XX
PF   24-SEP-1997;   97WO-US17103.
XX
PR   30-SEP-1996;   96US-0720565.
XX
PA   (LEUK-) LEUKOSITE INC.
XX
PI   Mackay CR,  Ponath PD;
XX
DR   WPI; 1998-286418/25.
DR   N-PSDB; AAV07402.
XX
PT   Antibodies to chemokine receptor-3 protein - useful for diagnosis
PT   and treatment of inflammatory conditions, e.g. allergy, asthma,
PT   autoimmune disease, graft rejection or cancer
XX
PS   Example 2; Fig 1A-C; 185pp; English.
XX
CC   This polypeptide comprises novel human C-C chemokine receptor 3,
CC   also designated CKR-3, CCR3 or Eos L2, that binds and mediates
CC   chemotaxis in response to chemokines such as eotaxin, RANTES and
CC   MCP-3.  Its amino acid sequence was deduced from an isolated
CC   genomic DNA sequence (see AAV07402).  It differs slightly from the
CC   sequence (see AAW51745) deduced from a cDNA clone (see AAV07403); a
CC   consensus sequence for CKR-3 is provided (see AAW51746).  The
CC   invention relates to isolated and/or recombinant nucleic acids
CC   encoding CKR-3, isolated or recombinant CKR-3 polypeptides,
CC   recombinant nucleic acid constructs, host cells useful for
CC   production of recombinant CKR-3 proteins, to antibodies reactive
CC   with the receptors, and to methods of using these products to
CC   identify ligands, antagonists and agonists of receptor function.
CC   Inhibitors of CKR-3 can be used to treat: inflammatory or allergic
CC   diseases and conditions, including respiratory allergic diseases
CC   such as asthma, allergic rhinitis, hypersensitivity lung disease,
CC   hypersensitivity pneumonitis, eosinophilic pneumonia (e.g.
CC   Loeffler's syndrome, chronic eosinophilic pneumonia, interstitial
CC   lung disease (ILD) e.g. idiopathic pulmonary fibrosis or ILD
CC   associated with rheumatoid arthritis, systemic lupus erythematosus,
CC   ankylosing spondylitis, systemic sclerosis, Sjogren's syndrome,
CC   polymyositis or dermatomyositis), systemic anaphylaxis or
CC   hypersensitivity responses, drug allergy, insect sting allergy,
CC   inflammatory bowel disease, such as Crohn's disease and ulcerative
CC   colitis, spondyloarthropathy, scleroderma, psoriasis, inflammatory
CC   dermatosis such as dermatitis, eczema, atopic dermatitis,
CC   allergic contact dermatitis, urticaria, vasculitis (e.g. necrotizing,
CC   cutaneous and hypersensitivity vasculitis); eosinphilic myositis
CC   and eosinophilic fasciitis; autoimmune diseases such as rheumatoid
CC   arthritis, psoriatic arthritis, multiple sclerosis, systemic lupus
CC   erythematosus, myasthenia gravis, juvenile onset diabetes,
CC   glomerulonephritis, autoimmune thyroiditis and Behcet's disease;
CC   graft rejection, including allograft rejection or graft-versus-host
CC   disease; cancers with leukocyte infiltration of the skin or organs;
CC   and also reperfusion injury, atherosclerosis, certain haematologic
CC   malignancies, septic shock and endotoxic shock.  Promoters of CKR-3
CC   function can be used for treating: immunosuppression e.g. in AIDS
CC   patients or individuals undergoing radiation therapy, chemotherapy,
CC   therapy for autoimmune disease or other drug therapy, and
CC   immunosuppression due congenital deficiency in receptor function or
CC   other causes; and infectious diseases such as parasitic diseases,
CC   including helminth infections, such as nematodes (round worms).
CC   The agents can also be used for detection and diagnosis.
XX
SQ   Sequence   355 AA;

  Query Match             99.6%;  Score 1846;  DB 19;  Length 355;
  Best Local Similarity   99.4%;  Pred. No. 4.7e-200;
  Matches  353;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60
              ||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||
Db          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTFGLLGNVVVVMILI 60

Qy         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120

Qy        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180

Qy        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240

Qy        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300
              |||||||||||||||||||||||||||||:||||||||||||||||||||||||||||||
Db        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERTKHLDLVMLVTEVIAYSHCCMNPVI 300

Qy        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355

RESULT 13
AAW25943
ID   AAW25943 standard; Protein; 356 AA.
XX
AC   AAW25943;
XX
DT   13-MAR-1998  (first entry)
XX
DE   Human CCKR3 chemokine receptor.
XX
KW   CCF18 chemokine; mouse; primer; PCR; amplification; antagonist; human;
KW   abnormal physiology; development; anti-viral; probe; hybridisation.
XX
OS   Homo sapiens.
```

```
XX
PN   WO9721812-A2.
XX
PD   19-JUN-1997.
XX
PF   05-DEC-1996;   96WO-US19139.
XX
PR   08-DEC-1995;   95US-0567882.
XX
PA   (SCHE ) SCHERING CORP.
XX
PI   Dairaghi DJ,  Hara T,  Miyajima A,  Schall TJ,  Wang W;
PI   Yoshimura A;
XX
DR   WPI; 1997-332784/30.
DR   N-PSDB; AAT79096.
XX
PT   New isolated chemokine CCF8 and chemokine receptor CCKR3 - used to
PT   develop products useful for the diagnosis and treatment of
PT   conditions associated with abnormal physiology or development
XX
PS   Claim 15; Page 60-62; 73pp; English.
XX
CC   This is the amino acid sequence of a novel CCKR3 chemokine receptor
CC   isolated from a Th0-activated human T-cell cDNA library using the
CC   sequence amplified by primers AAT79097 and AAT79098 as a probe.
CC   The encoded protein can be used to screen for (ant)agonists that bind
CC   to the novel CCF18 chemokines (AAW25941 and AAW25942).  These
CC   (ant)agonists are useful in the treatment of conditions associated with
CC   abnormal physiology or development.
XX
SQ   Sequence   356 AA;

  Query Match             98.5%;  Score 1826.5;  DB 18;  Length 356;
  Best Local Similarity   98.6%;  Pred. No. 7.6e-198;
  Matches  351;  Conservative    2;  Mismatches    2;  Indels    1;  Gaps    1;

Qy          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60

Qy         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120

Qy        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180

Qy        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240

Qy        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSH-CCMNPV 299
              |||||||||||||||||||||||||||||||||||| |||||||||| ||:||:
Db        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLDMLVTEVIAYSHWCCLNPL 300

Qy        300 IYAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
              ||||||||||||||||||||||||||||||||||||||||||| ||||||||
Db        301 IYAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTGEPELSIVF 356


RESULT 14
AAW03378
ID   AAW03378 standard; Protein; 355 AA.
XX
AC   AAW03378;
XX
DT   15-NOV-1996  (first entry)
XX
DE   CC-chemokine receptor 3 consensus sequence.
XX
KW   CC-chemokine receptor 3; CKP-3; Eos-L2; inhibitor; antisense;
KW   antiinflammatory; eosinophil.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 276
FT                   /label= Thr, Ser
XX
PN   WO9622371-A2.
XX
PD   25-JUL-1996.
XX
PF   19-JAN-1996;   96WO-US00608.
XX
PR   19-JAN-1995;   95US-0375199.
XX
PA   (BGHM ) BRIGHAM & WOMENS HOSPITAL.
PA   (CHIL-) CHILDRENS MEDICAL CENT.
PA   (LEUK-) LEUKOSITE INC.
XX
PI   Gerard CJ,  Gerard NP,  Mackay CR,  Ponath PD,  Post TW;
PI   Qin S;
XX
DR   WPI; 1996-354528/35.
DR   N-PSDB; AAT31336.
XX
PT   Mammalian chemokine receptor-3 and related nucleic acids - useful to
PT   identify receptor inhibitors to treat inflammatory disease, e.g.
PT   autoimmune disorders, certain cancers, etc.
XX
PS   Claim 10; Page 115-116; 153pp; English.
XX
CC   A consensus amino acid sequence (AAW03378) was produced for a novel
CC   human receptor, designated Eos L2 or C-C chemokine receptor 2 (CKR-3).
CC   It was obtd. by comparing the sequences (AAW03376-77) deduced from a
CC   CKR-3 genomic clone (AAT31334) and a cDNA clone (AAT31335).  Initial
CC   sequence information revealed 2 regions in which the cDNA sequence
CC   appeared to be shifted in frame, resulting in 2 sets of 4 contiguous
CC   amino acid differences in the predicted proteins.  Further sequence
CC   analysis revealed only a single difference between the 2 open
CC   reading frames, the genomic clone coding for threonine at position
CC   276 and the cDNA clone for serine.
XX
SQ   Sequence   355 AA;

  Query Match             96.1%;  Score 1781;  DB 17;  Length 355;
  Best Local Similarity   96.6%;  Pred. No. 1.1e-192;
  Matches  343;  Conservative    0;  Mismatches   12;  Indels    0;  Gaps    0;

Qy          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60

Qy         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120

Qy        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180

Qy        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240
              | ||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db        181 TXCSALYPEDTVYSWXXFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240

Qy        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300
              |||||||||||||||||||||    |||||||||    ||||||||||||||||||||
Db        241 IFVIMAVFFIFWTPYNVAILLSXXXXILFGNDCERXXXXDLVMLVTEVIAYSHCCMNPVI 300

Qy        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||
Db        301 YAFVGERFRKYLRHXFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
```

```
RESULT 15
AAW51746
ID   AAW51746 standard; Protein; 355 AA.
XX
AC   AAW51746;
XX
DT   28-SEP-1998  (first entry)
XX
DE   Human C-C chemokine receptor 3 consensus sequence.
XX
KW   C-C chemokine receptor 3; CKR-3; CCR3; Eos L2; human;
KW   G protein-coupled receptor; leukocyte; antibody; antagonist;
KW   inflammation; allergy; asthma; graft rejection; infection;
KW   autoimmune disease; drug screening; therapy.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 182
FT                   /note= "encoded by MTT"
FT   Misc-difference 196
FT                   /note= "encoded by AGS"
FT   Misc-difference 197
FT                   /note= "encoded by SAT"
FT   Misc-difference 263
FT                   /note= "encoded by TSC"
FT   Misc-difference 264
FT                   /note= "encoded by YWW"
FT   Misc-difference 265
FT                   /note= "encoded by YMA"
FT   Misc-difference 266
FT                   /note= "encoded by WYC"
FT   Misc-difference 276
FT                   /note= "encoded by MMG"
FT   Misc-difference 277
FT                   /note= "encoded by ARS"
FT   Misc-difference 278
FT                   /note= "encoded by MWY"
FT   Misc-difference 279
FT                   /note= "encoded by YKG"
FT   Misc-difference 315
FT                   /note= "encoded by TTS"
XX
PN   WO9814480-A1.
XX
PD   09-APR-1998.
XX
PF   24-SEP-1997;   97WO-US17103.
XX
PR   30-SEP-1996;   96US-0720565.
XX
PA   (LEUK-) LEUKOSITE INC.
XX
PI   Mackay CR,  Ponath PD;
XX
DR   WPI; 1998-286418/25.
DR   N-PSDB; AAV07404.
XX
PT   Antibodies to chemokine receptor-3 protein - useful for diagnosis
PT   and treatment of inflammatory conditions, e.g. allergy, asthma,
PT   autoimmune disease, graft rejection or cancer
XX
PS   Disclosure; Page 138-139; 185pp; English.
XX
CC   This amino acid sequence for human chemokine receptor-3 (CKR-3)
CC   is deduced from a consensus nucleic acid sequence (see AAV07404)
CC   constructed by alignment of a genomic DNA sequence (see AAV07402)
CC   and a cDNA clone (see AAV07403) coding for CKR-3, a novel G
CC   protein-coupled receptor that binds and mediates chemotaxis in
CC   response to chemokines such as eotaxin, RANTES and MCP-3.  Sequence
CC   comparison revealed 2 regions in the cDNA sequence that appeared to
CC   be shifted in frame, resulting from an insertion of a base followed
CC   by the deletion of a base, or the deletion of a base followed by the
CC   insertion of a base.  These alterations resulted in 4 contiguous
CC   amino acid differences in the predicted proteins (see AAW51744 and
CC   AAW51745) at positions 263-266 and 276-279, respectively.  In
CC   addition, the genomic clone codes for threonine (ACG) at position
CC   276 and the cDNA clone for serine (AGC).  CKR-3 nucleic acids,
CC   polypeptides, antibodies, agonists and antagonists are useful for
CC   diagnosis and treatment of inflammatory conditions, autoimmune
CC   diseases and infections.
XX
SQ   Sequence   355 AA;

  Query Match             96.1%;  Score 1781;  DB 19;  Length 355;
  Best Local Similarity   96.6%;  Pred. No. 1.1e-192;
  Matches  343;  Conservative    0;  Mismatches   12;  Indels    0;  Gaps    0;

Qy          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTTSLDTVETFGTTSYYDDVGLLCEKADTRALMAQFVPPLYSLVFTVGLLGNVVVVMILI 60

Qy         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KYRRLRIMTNIYLLNLAISDLLFLVTLPFWIHYVRGHNWVFGHGMCKLLSGFYHTGLYSE 120

Qy        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 IFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIVTWGLAVLAALPEFIFYETEELFEE 180

Qy        181 TLCSALYPEDTVYSWRHFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240
              | |||||||||||||  ||||||||||||||||||||||||||||||||||||||||||
Db        181 TXCSALYPEDTVYSWXXFHTLRMTIFCLVLPLLVMAICYTGIIKTLLRCPSKKKYKAIRL 240

Qy        241 IFVIMAVFFIFWTPYNVAILLSSYQSILFGNDCERSKHLDLVMLVTEVIAYSHCCMNPVI 300
              ||||||||||||||||||||    |||||||||    ||||||||||||||||||||
Db        241 IFVIMAVFFIFWTPYNVAILLSXXXXILFGNDCERXXXXDLVMLVTEVIAYSHCCMNPVI 300

Qy        301 YAFVGERFRKYLRHFFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||
Db        301 YAFVGERFRKYLRHXFHRHLLMHLGRYIPFLPSEKLERTSSVSPSTAEPELSIVF 355


Search completed: June 27, 2003, 18:12:30
Job time : 73 secs
```